Mazdutide vs Cotadutide

Mazdutide and Cotadutide are both dual GLP-1/glucagon receptor agonists studied for their effects on weight management and metabolic health. Mazdutide, developed by Innovent Biologics and Eli Lilly, has achieved regulatory approval in China for chronic weight management, marking a milestone for this peptide class. In contrast, Cotadutide, from AstraZeneca, has completed Phase II trials but faces an uncertain development path. Their differing dosing schedules—once-weekly for Mazdutide versus once-daily for Cotadutide—may influence tolerability and research outcomes. This comparison highlights key distinctions in mechanism, evidence base, and safety considerations to guide researchers in selecting the appropriate peptide for their studies.

Mazdutide (IBI362) is a once-weekly injectable dual GLP-1/glucagon receptor agonist with a molecular weight of approximately 4233.7 g/mol. Its mechanism combines GLP-1 receptor activation—which suppresses appetite and lowers glucose—with glucagon receptor activation, which increases energy expenditure and reduces hepatic fat. Approved in China in June 2024 for chronic weight management, it is the first dual GLP-1/glucagon agonist to receive regulatory approval worldwide. Phase III trials for type 2 diabetes are ongoing in China. Research indicates significant weight loss in Chinese adults with obesity, effective glycemic control, and reductions in hepatic fat content. These findings position Mazdutide as a promising candidate for metabolic disorders, though further studies are needed to confirm long-term outcomes.

Cotadutide (MEDI0382) is a once-daily injectable dual GLP-1/glucagon receptor agonist originally developed by MedImmune and later by AstraZeneca. Its mechanism mirrors Mazdutide's, combining GLP-1-mediated glucose lowering and appetite suppression with glucagon-mediated hepatic fat oxidation and energy expenditure. Phase II trials have been completed in type 2 diabetes, obesity, and NASH/MASH, showing reductions in liver fat and improvements in glycemic control. However, mixed results and AstraZeneca's portfolio prioritization have left its development status uncertain. Despite this, Cotadutide remains a valuable research tool for studying dual agonism in metabolic diseases, particularly for its effects on hepatic steatosis.

Both Mazdutide and Cotadutide are primarily studied for weight management and metabolic health, reflecting their shared mechanism as dual GLP-1/glucagon receptor agonists. These applications include investigating their effects on appetite suppression, glucose homeostasis, and energy expenditure. Neither peptide has been associated with unique additional research applications beyond these core areas. Researchers may choose between them based on dosing frequency (weekly vs. daily), regulatory status, or specific metabolic endpoints, such as hepatic fat reduction in NASH/MASH for Cotadutide or weight loss in obesity for Mazdutide.

Both peptides exhibit gastrointestinal side effects typical of GLP-1 agonists, including nausea, vomiting, and diarrhea. For Mazdutide, these effects are dose-dependent and generally transient, with a noted heart rate increase consistent with the GLP-1 class. Cotadutide also causes dose-dependent GI effects, which can be managed through titration. However, its once-daily dosing may lead to more pronounced peak-trough fluctuations, potentially increasing GI side effects compared to weekly formulations like Mazdutide. Researchers should consider these tolerability differences when designing studies, particularly for long-term administration.